Changes in rheology and red blood cell function under recombinant human erythropoietin therapy.
The rh-EPO is a potent drug to treat renal anaemia. RBC aggregation is not influenced by the rh-EPO therapy. Membrane elasticity and RBC deformability improve remarkably after rh-EPO which might benefit microcirculation. Rh-EPO therapy can not prolong RBC life span. Obviously uremic milieu alone determines RBC life time. Rh-EPO treatment corrects renal anemia by increasing the number of RBC and the RBC volume.
Schmidt
R
R
Department of Internal Medicine, University of Rostock, FRG.
Lerche
D
D
Dörp
E
E
Winkler
R
R
Klinkmann
H
H
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D004903:Erythrocyte Aggregation / Q000502:physiology; D004907:Erythrocyte Deformability / Q000502:physiology; D004912:Erythrocytes / Q000502:physiology*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin